Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Shares Shorted: Short Interest Up 104.5% in September

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the recipient of a large growth in short interest in September. As of September 30th, there was short interest totaling 98,600 shares, a growth of 104.5% from the September 15th total of 48,204 shares. Based on an average trading volume of 611,232 shares, the short-interest ratio is presently 0.2 days. Approximately 0.6% of the company’s stock are sold short.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ENLV. Wall Street Zen raised shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 29th. Zacks Research cut shares of Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, October 2nd. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Tuesday, September 22nd. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $247.50.

Enlivex Therapeutics Price Performance

NASDAQ ENLV opened at $0.22 on Wednesday. Enlivex Therapeutics has a 12 month low of $0.22 and a 12 month high of $27.15. The stock’s fifty day moving average price is $1.07 and its 200-day moving average price is $6.81.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ENLV. WINTON GROUP Ltd bought a new position in Enlivex Therapeutics during the second quarter valued at approximately $55,000. Susquehanna International Group LLP boosted its holdings in Enlivex Therapeutics by 1,428.5% in the second quarter. Susquehanna International Group LLP now owns 157,648 shares of the company’s stock worth $87,000 after purchasing an additional 147,334 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in Enlivex Therapeutics by 53.2% in the first quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock worth $121,000 after purchasing an additional 45,303 shares during the last quarter. 1.02% of the stock is owned by hedge funds and other institutional investors.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd. is a clinical-stage biotechnology company developing immunotherapies designed to restore immune-system balance in conditions associated with excessive or dysregulated inflammation. The company is based in Israel and trades on the Nasdaq under the symbol ENLV.

Enlivex’s lead product candidate is Allocetra, an investigational, off-the-shelf cell therapy intended to reprogram immune cells known as macrophages and promote immune homeostasis. The therapy is being studied as a potential treatment for severe inflammatory conditions, including sepsis and osteoarthritis of the knee.

The company’s clinical development activities have included studies in Israel and other locations, with programs focused on evaluating Allocetra’s safety and potential efficacy.